{"title":"Relationship of <i>Helicobacter pylori</i> Infection with Nonalcoholic Fatty Liver Disease: A Meta-Analysis.","authors":"Guangqin Xu, Shaoze Ma, Liyan Dong, Nahum Mendez-Sanchez, Hongyu Li, Xingshun Qi","doi":"10.1155/2023/5521239","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aims: </strong><i>Helicobacter pylori</i> (<i>H. pylori</i>) and nonalcoholic fatty liver disease (NAFLD) have become increasingly recognized, both of which affect human health globally. The association of <i>H. pylori</i> infection with NAFLD remains unclear.</p><p><strong>Methods: </strong>PubMed, EMBASE, and Cochrane Library databases were searched. Only a random-effects model was used. Odds ratios (ORs) and risk ratios (RRs) with 95% confidence intervals (CIs) were calculated for the combined estimates of raw data. Adjusted ORs (aORs) and hazard ratios (aHRs) with 95% CIs were calculated for the combined estimates of data adjusted for confounders.</p><p><strong>Results: </strong>Thirty-four studies with 218573 participants were included. Based on unadjusted data from 26 cross-sectional studies and 3 case-control studies, <i>H. pylori</i> infection was significantly associated with the presence of NAFLD (OR = 1.26, 95% CI = 1.17-1.36, <i>P</i> < 0.001). Based on adjusted data from 15 cross-sectional studies and 1 case-control study, <i>H. pylori</i> infection was significantly associated with the presence of NAFLD (aOR = 1.25, 95% CI = 1.08-1.44, <i>P</i> < 0.001). Compared with control subjects without NAFLD, patients with moderate (OR = 1.67, 95% CI = 1.17-2.39, <i>P</i> = 0.005) and severe (OR = 1.71, 95% CI = 1.30-2.24, <i>P</i> < 0.001) NAFLD, but not those with mild NAFLD (OR = 1.14, 95% CI = 0.9-1.45, <i>P</i> = 0.286), had significantly higher proportions of <i>H. pylori</i> infection. The association of <i>H. pylori</i> infection with the occurrence of NAFLD was statistically significant based on adjusted data from 3 cohort studies (aHR = 1.18, 95% CI = 1.05-1.34, <i>P</i> = 0.007), but not based on unadjusted data from 3 cohort studies (RR = 1.41, 95% CI = 0.80-2.48, <i>P</i> = 0.237).</p><p><strong>Conclusion: </strong><i>H. pylori</i> infection is associated with NAFLD, especially moderate and severe NAFLD. The impact of <i>H. pylori</i> eradication on the prevention of NAFLD should be further explored.</p>","PeriodicalId":48755,"journal":{"name":"Canadian Journal of Gastroenterology and Hepatology","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891807/pdf/","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Journal of Gastroenterology and Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2023/5521239","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 3
Abstract
Background and aims: Helicobacter pylori (H. pylori) and nonalcoholic fatty liver disease (NAFLD) have become increasingly recognized, both of which affect human health globally. The association of H. pylori infection with NAFLD remains unclear.
Methods: PubMed, EMBASE, and Cochrane Library databases were searched. Only a random-effects model was used. Odds ratios (ORs) and risk ratios (RRs) with 95% confidence intervals (CIs) were calculated for the combined estimates of raw data. Adjusted ORs (aORs) and hazard ratios (aHRs) with 95% CIs were calculated for the combined estimates of data adjusted for confounders.
Results: Thirty-four studies with 218573 participants were included. Based on unadjusted data from 26 cross-sectional studies and 3 case-control studies, H. pylori infection was significantly associated with the presence of NAFLD (OR = 1.26, 95% CI = 1.17-1.36, P < 0.001). Based on adjusted data from 15 cross-sectional studies and 1 case-control study, H. pylori infection was significantly associated with the presence of NAFLD (aOR = 1.25, 95% CI = 1.08-1.44, P < 0.001). Compared with control subjects without NAFLD, patients with moderate (OR = 1.67, 95% CI = 1.17-2.39, P = 0.005) and severe (OR = 1.71, 95% CI = 1.30-2.24, P < 0.001) NAFLD, but not those with mild NAFLD (OR = 1.14, 95% CI = 0.9-1.45, P = 0.286), had significantly higher proportions of H. pylori infection. The association of H. pylori infection with the occurrence of NAFLD was statistically significant based on adjusted data from 3 cohort studies (aHR = 1.18, 95% CI = 1.05-1.34, P = 0.007), but not based on unadjusted data from 3 cohort studies (RR = 1.41, 95% CI = 0.80-2.48, P = 0.237).
Conclusion: H. pylori infection is associated with NAFLD, especially moderate and severe NAFLD. The impact of H. pylori eradication on the prevention of NAFLD should be further explored.
背景和目的:幽门螺杆菌(h.p ylori)和非酒精性脂肪性肝病(NAFLD)越来越受到重视,两者都影响着全球人类健康。幽门螺杆菌感染与NAFLD的关系尚不清楚。方法:检索PubMed、EMBASE和Cochrane图书馆数据库。只使用了随机效应模型。对原始数据的综合估计计算95%置信区间(ci)的优势比(ORs)和风险比(rr)。对经混杂因素调整后的数据进行合并估计,计算95% ci的调整后or (aORs)和风险比(aHRs)。结果:34项研究共纳入218573名受试者。基于来自26个横断面研究和3个病例对照研究的未经调整的数据,幽门螺杆菌感染与NAFLD的存在显著相关(OR = 1.26, 95% CI = 1.17-1.36, P < 0.001)。根据15项横断面研究和1项病例对照研究的校正数据,幽门螺杆菌感染与NAFLD存在显著相关(aOR = 1.25, 95% CI = 1.08-1.44, P < 0.001)。与非NAFLD对照组相比,中度NAFLD患者(OR = 1.67, 95% CI = 1.17-2.39, P = 0.005)和重度NAFLD患者(OR = 1.71, 95% CI = 1.30-2.24, P < 0.001)幽门螺杆菌感染比例显著高于轻度NAFLD患者(OR = 1.14, 95% CI = 0.9% -1.45, P = 0.286)。根据3项队列研究的校正数据,幽门螺杆菌感染与NAFLD发生的相关性有统计学意义(aHR = 1.18, 95% CI = 1.05-1.34, P = 0.007),但根据3项队列研究的未校正数据,幽门螺杆菌感染与NAFLD发生的相关性无统计学意义(RR = 1.41, 95% CI = 0.80-2.48, P = 0.237)。结论:幽门螺杆菌感染与NAFLD相关,尤其是中重度NAFLD。根除幽门螺杆菌对NAFLD预防的影响有待进一步探讨。
期刊介绍:
Canadian Journal of Gastroenterology and Hepatology is a peer-reviewed, open access journal that publishes original research articles, review articles, and clinical studies in all areas of gastroenterology and liver disease - medicine and surgery.
The Canadian Journal of Gastroenterology and Hepatology is sponsored by the Canadian Association of Gastroenterology and the Canadian Association for the Study of the Liver.